RFK Jr. Predicts 'Enormous Demand' for Psychedelic Therapy After Trump Order

September 12, 2026

Photo via Pexels.

Robert F. Kennedy Jr. isn't shy about predicting big things for psychedelic medicine, and his latest comments came from an unlikely pulpit: his own podcast, produced in-house at the Department of Health and Human Services. Interviewing Bryan Hubbard, CEO of the advocacy group Americans for Ibogaine, the HHS Secretary said he expects "enormous demand" once psychedelic treatments become legally available to patients, with veterans topping the list of people who'd show up first.

Kennedy framed the moment as a turning point, crediting President Trump as the first occupant of the Oval Office willing to personally champion psychedelic therapy rather than leave it to agencies to sort out quietly. That framing lines up with an April 18, 2026 executive order Trump signed directing federal agencies to speed up research and review of these compounds. But there's a gap between the political energy radiating out of the administration and the plain regulatory fact that psilocybin, ibogaine, and MDMA all still sit in Schedule I, the DEA's most restrictive category, reserved for substances deemed to have no accepted medical use. That tension between momentum and machinery is the real story here.

What Kennedy Actually Said

Photo by Alpha En via Pexels.

Kennedy's remarks came in a conversational format he's leaned on since taking over HHS, using an agency-produced podcast to interview allies rather than face independent press. His guest, Bryan Hubbard, has spent the last several years building the case for ibogaine, a psychoactive alkaloid derived from the iboga plant, as a treatment for opioid addiction, PTSD, and traumatic brain injury, conditions disproportionately common among combat veterans. Kennedy didn't just talk up demand, though. He got specific about supply, telling Hubbard that treating veterans at scale would require more than 100 hours of dedicated support staff per patient. That's not a rhetorical flourish; ibogaine and similar compounds typically require medical monitoring, psychological preparation, and integration support around the dosing session itself, unlike a pill you take and go home with. Kennedy described this staffing math as an expense problem layered on top of a demand problem, meaning even if every regulatory door swings open tomorrow, the country doesn't currently have the clinical workforce to serve the patients who'd want in.

He also gave a behind-the-scenes account of how Trump came to embrace the issue, saying the president 'got it in his head' that he wanted to act and pushed the effort personally rather than letting it languish in agency review. Kennedy pointed to a specific moment as pivotal: podcaster Joe Rogan introducing Trump to a group of veterans in the Oval Office around the time of the executive order signing. According to Kennedy, that face-to-face meeting broke down whatever hesitation existed at the top, turning an abstract policy debate into something Trump experienced as a personal cause.

Inside Trump's Executive Order

Photo via Unsplash.

The executive order at the center of all this, titled Accelerating Medical Treatments for Serious Mental Illness, was signed April 18, 2026, and it reads like an attempt to unclog several bottlenecks at once. It directs the FDA to prioritize review of psychedelic compounds moving through the drug approval pipeline and instructs the DEA to ease research restrictions that have historically made it slow and expensive for scientists to even study Schedule I substances. It also allocates $50 million toward federal-state collaboration on psychedelic research, a relatively modest sum but a notable federal endorsement given how politically radioactive this category of drugs has been for decades.

The signing itself doubled as something of a show of force for the psychedelic-medicine coalition. Kennedy was there, along with Joe Rogan, FDA Commissioner Marty Makary, Bryan Hubbard, and former Navy SEAL Marcus Luttrell, whose presence underscored the veteran-centered framing of the whole initiative. Trump said the order would clear away bureaucratic hurdles, improve data sharing between the FDA and the VA so veteran outcomes could actually inform approvals, and speed up rescheduling for any psychedelic drug that clears FDA approval, meaning it wouldn't have to sit in Schedule I limbo even after being deemed safe and effective.

Makary, for his part, put a number on what acceleration could look like in practice, suggesting that approvals aligned with administration priorities could take weeks rather than the year or more that's typical for novel compounds. That's an aggressive timeline by FDA standards, and it's the detail that's drawing the most scrutiny from people who watch drug approval processes for a living.

Still Schedule I: The Legal Reality

Photo by Towfiqu barbhuiya via Unsplash.

Here's the part the executive order can't wave away: psilocybin, ibogaine, and MDMA are all still Schedule I under federal law right now, today, regardless of what any executive order says about speeding things up. That classification legally means the DEA considers them to have no currently accepted medical use and a high potential for abuse, the same category as heroin. An executive order can direct agencies to move faster and reduce friction, but it can't unilaterally reschedule a drug or approve a treatment; that still requires the FDA to sign off on specific applications and the DEA to act on rescheduling petitions separately.

That said, there's real movement happening within the existing framework. The FDA has granted fast-track review status to three separate companies studying psilocybin for treatment-resistant depression and major depressive disorder, a designation meant to speed development of drugs that address serious unmet medical needs. Methylone, a compound with MDMA-like effects, has similarly been fast-tracked as a potential PTSD treatment, and a phase 1 trial has been approved for noribogaine hydrochloride, a metabolite of ibogaine that researchers hope will offer similar therapeutic benefits with a cleaner safety profile.

It's worth remembering how recently this field hit a wall. Under the Biden administration, the FDA rejected an MDMA-assisted therapy application for PTSD, citing flawed trial data and ordering an entirely new study before reconsidering. State law adds another layer of complexity on top of all this federal back-and-forth, with psychedelic and cannabis-adjacent substances treated very differently from state to state. Readers should confirm their own state's law before assuming any of this translates to legal access where they live.

Texas, Veterans, and the Push From the Ground Up

Photo via Pexels.

If there's a place already testing what federal-level enthusiasm looks like on the ground, it's Texas. State lawmakers approved $50 million to study ibogaine as a treatment for opioid addiction, PTSD, and other conditions, a program that stands out both for its size and for who's backing it. Veterans groups pushed hard for the legislation, and former Governor Rick Perry lent his political weight to getting the bill through a legislature that isn't exactly known for embracing Schedule I substances in any other context.

That Texas program matters beyond its borders because it's functioning as a proof of concept, a state-funded research effort that federal officials can point to as evidence this isn't purely a fringe cause. Veterans have been the consistent through-line in this entire political shift, from the Oval Office meeting Kennedy described to the messaging around both the Texas program and the federal executive order. It's a strategically smart frame: veterans dealing with treatment-resistant PTSD, traumatic brain injury, and opioid dependence are sympathetic figures across the political spectrum in a way that psychedelic advocacy alone has never quite managed to be.

But Kennedy's own comment about staffing, that treating veterans at scale would demand more than 100 hours of support staff per patient, is a reminder that political sympathy doesn't build clinics or train clinicians. Even a fully rescheduled, fully FDA-approved ibogaine or psilocybin therapy would need a workforce of trained monitors, therapists, and medical staff that simply doesn't exist yet in sufficient numbers. Scaling this nationally, especially through a system as large and logistically strained as the VA, is a staffing and infrastructure problem that no executive order can solve by itself.

Why Some Researchers Are Nervous

Photo via Pexels.

Not everyone watching this unfold is convinced speed is the right goal. Philip Corlett, a psychiatry researcher at Yale who studies perception and psychosis, has been among the voices warning that short-circuiting rigorous clinical trial standards could damage the field's credibility for years to come, even if the immediate political intent is to help patients faster. The concern isn't that psychedelics don't work; it's that approving them before the data is solid enough could produce safety problems, inconsistent outcomes, or public backlash that sets the whole research agenda back further than a slower, more careful pace would have.

That worry sits uncomfortably next to Commissioner Makary's suggestion that priority reviews could take weeks instead of the year-plus that's standard for novel therapeutics. Multi-year review timelines exist for reasons that go beyond bureaucratic caution; they're built to catch problems in trial design, dosing, and patient selection before a drug reaches millions of people. Compressing that process, even for a well-intentioned cause, changes the risk calculus in ways regulators haven't fully reckoned with in public.

The MDMA rejection is the clearest precedent for how this can go wrong. Regulators looked at the trial data underlying that application and decided it wasn't good enough, ordering a new study rather than approving a therapy that had, by that point, built significant public and patient expectation around it. That episode is a useful check on the current wave of optimism: political will and administration priorities didn't get MDMA over the finish line then, and there's no guarantee they'll be sufficient this time either if the underlying trial data doesn't hold up to scrutiny.

What's notable about this moment isn't just that a sitting president is pushing psychedelic therapy, it's how personal Trump's involvement seems to be, and how directly Kennedy is willing to say so on the record. That's a different posture than the cautious, agency-driven pace this field has moved at for years. But Kennedy's own admission about staffing, that scaling veteran treatment could require over 100 hours of support per patient, is the tell that the harder problem here was never really scheduling. It's workforce, infrastructure, and the unglamorous work of building a clinical system that can actually deliver these treatments safely at volume.

Veterans are almost certainly going to be the first real test of whether any of this translates into actual patient access. Between the Texas ibogaine program, the Oval Office optics, and the VA data-sharing push written into the executive order, the political and logistical machinery is being built around veteran populations first. Whether that becomes a genuine national model or stays a handful of state-level pilot programs depends on money and staffing more than any presidential signature.

Ultimately, this comes down to a race between political urgency and regulatory rigor. If Makary's weeks-not-years timeline holds up and the underlying trial data is strong enough to survive scrutiny, this could be the moment psychedelic therapy finally moves from advocacy talking point to durable medical pathway. If it doesn't, and corners get cut the way critics fear, this could end up looking a lot like that earlier MDMA episode, another high-profile psychedelic treatment stalled out at the FDA's door, data in hand but not good enough.